ImmunityBio Inc (NASDAQ: IBRX) kicked off on Friday, down -12.13% from the previous trading day, before settling in for the closing price of $7.34. Over the past 52 weeks, IBRX has traded in a range of $1.83-$8.28.
Annual sales at Healthcare sector company grew by 2.39% over the past five years. While this was happening, its average annual earnings per share was recorded 34.64%. With a float of $330.90 million, this company’s outstanding shares have now reached $984.97 million.
ImmunityBio Inc (IBRX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of ImmunityBio Inc is 66.42%, while institutional ownership is 14.65%. The most recent insider transaction that took place on Jan 20 ’26, was worth 1,094,297. In this transaction Director of this company sold 151,967 shares at a rate of $7.20, taking the stock ownership to the 3,091,604 shares. Before that another transaction happened on Jan 16 ’26, when Company’s Director sold 50,000 for $5.00, making the entire transaction worth $250,000. This insider now owns 0 shares in total.
ImmunityBio Inc (IBRX) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.08 earnings per share (EPS), higher than consensus estimate (set at -0.13) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 63.41% during the next five years compared to 2.39% growth over the previous five years of trading.
ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators
Take a look at ImmunityBio Inc’s (IBRX) current performance indicators. Last quarter, stock had a quick ratio of 5.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 76.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.42, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.28 in one year’s time.
